Heartflow (NASDAQ:HTFL) Reaches New 52-Week High – Should You Buy?

Heartflow, Inc. (NASDAQ:HTFL)’s share price reached a new 52-week high during trading on Wednesday. The stock traded as high as $60.66 and last traded at $60.0040, with a volume of 852,071 shares traded. The stock had previously closed at $55.80.

Recent Heartflow Headlines

Here are a few of the latest headlines about HTFL:

• Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
• Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Canaccord Genuity Group upped their price target on shares of Heartflow from $56.00 to $69.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley increased their price target on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. Finally, Stifel Nicolaus raised their price objective on shares of Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $56.25.

Heartflow Price Performance

The company has a 50-day moving average price of $51.93 and a 200-day moving average price of $35.14. The firm has a market capitalization of $5.21 billion, a PE ratio of -32.74 and a beta of 2.50.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.15. The business had revenue of $72.86 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. During the same period in the previous year, the business earned ($0.27) EPS. On average, research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Heartflow

In other Heartflow news, CFO Vikram Verghese sold 29,714 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the sale, the chief financial officer directly owned 184,789 shares of the company’s stock, valued at $9,250,537.34. This trade represents a 13.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of Heartflow stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total transaction of $1,316,554.33. Following the sale, the insider owned 73,453 shares of the company’s stock, valued at approximately $4,040,649.53. This trade represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 332,403 shares of company stock worth $16,602,786. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XXEC Inc. purchased a new position in shares of Heartflow during the 2nd quarter worth about $2,524,764,000. BlackRock Inc. purchased a new stake in Heartflow in the second quarter valued at approximately $152,502,000. Bamco Inc. NY purchased a new stake in Heartflow in the second quarter valued at approximately $94,625,000. Jupiter Topco LLC acquired a new position in Heartflow during the second quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC increased its position in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter.

About Heartflow

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.